Whittier Trust Co. Grows Position in Baxter International Inc. $BAX

Whittier Trust Co. boosted its position in shares of Baxter International Inc. (NYSE:BAX) by 82.2% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,202 shares of the medical instruments supplier’s stock after acquiring an additional 1,445 shares during the quarter. Whittier Trust Co.’s holdings in Baxter International were worth $97,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Horizon Investments LLC boosted its holdings in Baxter International by 5.0% during the 1st quarter. Horizon Investments LLC now owns 7,438 shares of the medical instruments supplier’s stock valued at $255,000 after acquiring an additional 351 shares during the period. Archer Investment Corp boosted its holdings in Baxter International by 20.5% during the 1st quarter. Archer Investment Corp now owns 2,935 shares of the medical instruments supplier’s stock valued at $100,000 after acquiring an additional 500 shares during the period. Private Trust Co. NA boosted its holdings in Baxter International by 17.3% during the 1st quarter. Private Trust Co. NA now owns 3,822 shares of the medical instruments supplier’s stock valued at $131,000 after acquiring an additional 565 shares during the period. Nicholas Hoffman & Company LLC. boosted its holdings in Baxter International by 2.0% during the 1st quarter. Nicholas Hoffman & Company LLC. now owns 31,739 shares of the medical instruments supplier’s stock valued at $1,086,000 after acquiring an additional 636 shares during the period. Finally, Anchor Investment Management LLC boosted its holdings in Baxter International by 3.4% during the 1st quarter. Anchor Investment Management LLC now owns 21,164 shares of the medical instruments supplier’s stock valued at $724,000 after acquiring an additional 701 shares during the period. 90.19% of the stock is currently owned by hedge funds and other institutional investors.

Baxter International Stock Performance

Shares of BAX opened at $22.99 on Friday. The stock has a 50-day simple moving average of $23.43 and a 200-day simple moving average of $27.14. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.49 and a current ratio of 2.30. The stock has a market capitalization of $11.81 billion, a PE ratio of -76.65, a PEG ratio of 0.75 and a beta of 0.58. Baxter International Inc. has a 1 year low of $21.33 and a 1 year high of $37.74.

Baxter International (NYSE:BAX) last announced its quarterly earnings data on Thursday, July 31st. The medical instruments supplier reported $0.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.60 by ($0.01). Baxter International had a negative net margin of 1.42% and a positive return on equity of 16.96%. The company had revenue of $2.81 billion during the quarter, compared to analysts’ expectations of $2.82 billion. During the same quarter in the previous year, the business posted $0.68 EPS. The business’s quarterly revenue was up 4.3% compared to the same quarter last year. Baxter International has set its Q3 2025 guidance at 0.580-0.620 EPS. FY 2025 guidance at 2.420-2.520 EPS. On average, analysts predict that Baxter International Inc. will post 2.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Stifel Nicolaus restated a “hold” rating and set a $25.00 target price (down from $36.00) on shares of Baxter International in a report on Monday, August 4th. Barclays lowered their target price on Baxter International from $41.00 to $36.00 and set an “overweight” rating for the company in a report on Monday, August 4th. The Goldman Sachs Group cut Baxter International from a “buy” rating to a “neutral” rating and set a $25.00 target price for the company. in a report on Friday, August 1st. Wells Fargo & Company decreased their price objective on Baxter International from $33.00 to $24.00 and set an “equal weight” rating for the company in a research note on Friday, August 1st. Finally, Wall Street Zen cut Baxter International from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Three analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $28.89.

Baxter International Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.